Game On: Court Ruling on Myriad Patents to Kick off Protracted Legal Battle Over DNA Patentability
March 31, 2010
Game On: Court Ruling on Myriad Patents to Kick off Protracted Legal Battle Over DNA Patentability
A US District Court's ruling that Myriad's BRCA patents are invalid will definitely be appealed in the Federal Circuit, and will probably reach the Supreme Court, according to legal experts.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010 / Pharmacogenomics Reporter - ACLU, PUBPAT Seek to Challenge Patentability of Isolated Genes Before Supreme Court
October 12, 2011 / Pharmacogenomics Reporter - US DoJ Argues Against Patenting Isolated Genes, But USPTO Will Maintain Status Quo
November 3, 2010 / Pharmacogenomics Reporter - If US Court's Decision Against Gene Patenting Sticks, Will EU Researchers Take Up Similar Cause?
March 31, 2010 / Pharmacogenomics Reporter - UPDATE: Appeals Court Decides Isolated DNA Patentable, Myriad's Analytical Method Claims Not
August 3, 2011 / Pharmacogenomics Reporter